CLINICAL TRIALS PROFILE FOR PHENTERMINE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for PHENTERMINE HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000506 ↗ | Cardiovascular System in Obesity: Effect of Treatment | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 | 1983-05-01 | To determine the long-term efficacy of the combination therapy of phentermine and fenfluramine in conjunction with diet, exercise, and behavior modification in the treatment of simple, moderate obesity. |
| NCT00402077 ↗ | A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects | Completed | AstraZeneca | Phase 2 | 2006-11-01 | This study will examine the safety, tolerability, and body weight effect of subcutaneous pramlintide alone and in various combinations with the oral antiobesity agents sibutramine or phentermine in overweight and obese subjects. |
| NCT00518466 ↗ | Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults | Completed | VIVUS, Inc. | Phase 1 | 2007-07-01 | The primary objective of this study is to describe the single- and multiple-dose pharmacokinetic profiles of two novel formulations of topiramate and commercially available immediate release topiramate, all dosed with immediate release phentermine. |
| NCT00563368 ↗ | A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults | Completed | Medpace, Inc. | Phase 3 | 2007-12-01 | The objective of this study is to evaluate the safety and efficacy of various doses of VI-0521 compared to both placebo, and the single-agent components that comprise each combination dose. This study will provide confirmatory data to demonstrate that doses of VI-0521 have efficacy that is greater than placebo and each of the single-agent components that comprise the combination dose. |
| NCT00563368 ↗ | A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults | Completed | VIVUS, Inc. | Phase 3 | 2007-12-01 | The objective of this study is to evaluate the safety and efficacy of various doses of VI-0521 compared to both placebo, and the single-agent components that comprise each combination dose. This study will provide confirmatory data to demonstrate that doses of VI-0521 have efficacy that is greater than placebo and each of the single-agent components that comprise the combination dose. |
| NCT00600067 ↗ | A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults | Completed | Sentrx | Phase 2 | 2008-01-01 | The purpose of the study is to determine the long-term safety and efficacy of VI-0521 (phentermine/topiramate) compared to placebo in providing blood sugar control in Type 2 diabetic adults. Continuation of initial 6 month trial. |
| NCT00600067 ↗ | A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults | Completed | Synteract, Inc. | Phase 2 | 2008-01-01 | The purpose of the study is to determine the long-term safety and efficacy of VI-0521 (phentermine/topiramate) compared to placebo in providing blood sugar control in Type 2 diabetic adults. Continuation of initial 6 month trial. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PHENTERMINE HYDROCHLORIDE
Condition Name
Clinical Trial Locations for PHENTERMINE HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for PHENTERMINE HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for PHENTERMINE HYDROCHLORIDE
Sponsor Name
